HK1011611A1 - Use of l-deprenyl for retarding age dependent deterioration of the immune system function in mammals - Google Patents

Use of l-deprenyl for retarding age dependent deterioration of the immune system function in mammals

Info

Publication number
HK1011611A1
HK1011611A1 HK98112656A HK98112656A HK1011611A1 HK 1011611 A1 HK1011611 A1 HK 1011611A1 HK 98112656 A HK98112656 A HK 98112656A HK 98112656 A HK98112656 A HK 98112656A HK 1011611 A1 HK1011611 A1 HK 1011611A1
Authority
HK
Hong Kong
Prior art keywords
deprenyl
mammals
immune system
system function
dependent deterioration
Prior art date
Application number
HK98112656A
Other languages
English (en)
Inventor
Norton W Milgram
David R Stevens
Gwendolyn O Ivy
Original Assignee
Deprenyl Animal Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27076843&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1011611(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US07/576,011 external-priority patent/US5151449A/en
Application filed by Deprenyl Animal Health Inc filed Critical Deprenyl Animal Health Inc
Publication of HK1011611A1 publication Critical patent/HK1011611A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thin Film Transistor (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pulse Circuits (AREA)
  • Electrotherapy Devices (AREA)
HK98112656A 1990-08-31 1998-12-02 Use of l-deprenyl for retarding age dependent deterioration of the immune system function in mammals HK1011611A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/576,011 US5151449A (en) 1990-08-31 1990-08-31 Use of L-deprenyl for retention of specific physiological functions
US64345291A 1991-01-18 1991-01-18

Publications (1)

Publication Number Publication Date
HK1011611A1 true HK1011611A1 (en) 1999-07-16

Family

ID=27076843

Family Applications (1)

Application Number Title Priority Date Filing Date
HK98112656A HK1011611A1 (en) 1990-08-31 1998-12-02 Use of l-deprenyl for retarding age dependent deterioration of the immune system function in mammals

Country Status (16)

Country Link
US (2) US5276057A (da)
EP (2) EP0732101B1 (da)
JP (3) JP2819072B2 (da)
AT (2) ATE149350T1 (da)
AU (1) AU633714B2 (da)
BR (1) BR9103506A (da)
CA (1) CA2039194C (da)
DE (2) DE69131386T2 (da)
DK (2) DK0732101T3 (da)
ES (2) ES2097790T3 (da)
GR (2) GR3022971T3 (da)
HK (1) HK1011611A1 (da)
ID (1) ID19492A (da)
MX (1) MX9100067A (da)
MY (2) MY110217A (da)
NZ (1) NZ238277A (da)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2039194C (en) * 1990-08-31 1997-01-28 Norton W. Milgram Uses of l-deprenyl and compositions for same
US5565495A (en) * 1990-08-31 1996-10-15 Deprenyl Animal Health, Inc. Method for survival curve shifting in dogs
US5561163A (en) * 1990-08-31 1996-10-01 Deprenyl Animal Health, Inc. Treating hearing loss with deprenyl
US5767164A (en) * 1991-04-04 1998-06-16 Innovations Foundation Use of deprenyl to rescue damaged nerve cells
CA2107552C (en) * 1991-04-04 2001-08-28 William G. Tatton Use of deprenyl to maintain, prevent loss, or recover nerve cell function
US5444095A (en) * 1991-04-04 1995-08-22 University Of Toronto, Innovations Foundation Use of deprenyl to rescue damaged nerve cells
US5844003A (en) * 1991-04-04 1998-12-01 Innovations Foundation Use of deprenyl compounds to maintain, prevent loss, or recover nerve cell function
US5242950A (en) * 1992-04-23 1993-09-07 Somerset Pharmaceuticals, Inc. Treatment of macular degeneration
US5817336A (en) * 1993-04-02 1998-10-06 Orion-Yhtyma Oy Composition containing selegiline
DE69425345T2 (de) * 1993-05-04 2001-03-01 Ceva Sante Animale Libourne Anwendung von Selegilin in Tiermedizin
FR2704756B1 (fr) * 1993-05-04 1995-07-28 Sanofi Elf Utilisation de la sélégiline en médecine vétérinaire.
US6033682A (en) 1995-01-13 2000-03-07 Somerset Pharmaceuticals, Inc. S(+) desmethylselegiline and its use in therapeutic methods and pharmaceutical compositions
JP3036847B2 (ja) 1995-01-13 2000-04-24 サマーセット・ファーマシューティカルズ・インコーポレイテッド デスメチルセレギリンを用いる方法および医薬組成物
EP0808160A1 (en) 1995-02-10 1997-11-26 The University Of Toronto Innovations Foundation Deprenyl compounds for treatment of glaucoma
US6316022B1 (en) 1995-06-07 2001-11-13 Noven Pharmaceuticals, Inc. Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures
IL122484A0 (en) * 1995-06-07 1998-06-15 Noven Pharma Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures
DK0866691T4 (da) * 1995-11-06 2005-06-06 Somerset Pharmaceuticals Inc Medikamenter til sublingual og bukkal administration af selegilin
CA2322878C (en) 1998-03-16 2008-05-06 Somerset Pharmaceuticals, Inc. Use of selegiline or desmethylselegiline for treating wounds, burns and dermatological damage
US20030212144A1 (en) * 2001-07-18 2003-11-13 Mohankumar Sheba J.J. Method for inducing an estrous cycle and pregnancy in a female mammal
EP1565185A4 (en) * 2002-11-07 2011-01-05 Technion Res & Dev Foundation NEUROPROTECTIVE IRON CHELATORS AND PHARMACEUTICAL COMPOSITIONS THEREWITH
US20050009862A1 (en) * 2003-04-25 2005-01-13 Sabounjian Luann Method for promoting uninterrupted sleep by administration of trospium chloride
EP1686973A4 (en) * 2003-11-25 2009-03-25 Technion Res & Dev Foundation COMPOSITIONS AND METHODS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES AND DISEASES
US8097608B2 (en) * 2003-11-25 2012-01-17 Technion Research And Development Foundation Ltd. Methods for treatment of cardiovascular disorders and diseases
JP2005232148A (ja) * 2004-02-03 2005-09-02 Technion Research & Development Foundation Ltd 神経保護剤としてプロパルギルアミンの使用
FR2884421B1 (fr) 2005-04-15 2007-08-10 Virbac Sa Nouveaux moyens de regulation des troubles du comportement chez les animaux de compagnie
US8263655B2 (en) * 2005-10-06 2012-09-11 Technion Research And Development Foundation Ltd Methods for treatment of renal failure
CN102665704A (zh) 2009-12-29 2012-09-12 希尔氏宠物营养品公司 用于伴侣动物的包含丙酮酸盐的组合物及其使用方法
PL2531181T3 (pl) 2010-02-03 2019-09-30 Pharma Two B Ltd. Preparaty rasagiliny o przedłużonym uwalnianiu i ich zastosowanie
CN103860503A (zh) * 2012-12-10 2014-06-18 天津市汉康医药生物技术有限公司 一种治疗帕金森病的缓释药物组合物及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA871155A (en) * 1971-05-18 Chinoin Gyogyszer-Es Vegyeszeti Termekek Gyara Rt Optically active phenyl isopropylamine derivatives having pharmaceutical properties and their preparation
HU187775B (en) * 1982-07-14 1986-02-28 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt,Hu New process for producing propargile-amines of pharmaceutical activity
US4916151A (en) * 1985-12-05 1990-04-10 Merrell Dow Pharmaceuticals Inc. Method of treating parkinson's syndrome
US4871550A (en) * 1986-09-05 1989-10-03 Millman Phillip L Nutrient composition for athletes and method of making and using the same
US4880883A (en) * 1987-06-03 1989-11-14 Wisconsin Alumni Research Foundation Biocompatible polyurethanes modified with lower alkyl sulfonate and lower alkyl carboxylate
US4861800A (en) * 1987-08-18 1989-08-29 Buyske Donald A Method for administering the drug deprenyl so as to minimize the danger of side effects
HU208484B (en) * 1988-08-17 1993-11-29 Chinoin Gyogyszer Es Vegyeszet Process for producing pharmaceutical composition containing acid additional salt of selegilin as active component for treating schisofrenia
US5192808A (en) * 1990-08-31 1993-03-09 Deprenyl Animal Health, Inc. Therapeutic effect of L-deprenyl in the management of pituitary-dependent hyperadrenocorticism (cushing's disease)
CA2039194C (en) * 1990-08-31 1997-01-28 Norton W. Milgram Uses of l-deprenyl and compositions for same

Also Published As

Publication number Publication date
JPH09328422A (ja) 1997-12-22
DE69131386D1 (de) 1999-07-29
ATE181501T1 (de) 1999-07-15
EP0473252B1 (en) 1997-03-05
DE69131386T2 (de) 1999-11-25
JPH04230624A (ja) 1992-08-19
NZ238277A (en) 1993-10-26
JPH09328423A (ja) 1997-12-22
EP0732101A1 (en) 1996-09-18
JP2819072B2 (ja) 1998-10-30
ES2135123T3 (es) 1999-10-16
JP2884501B2 (ja) 1999-04-19
US5387615A (en) 1995-02-07
ES2097790T3 (es) 1997-04-16
JP2884500B2 (ja) 1999-04-19
AU633714B2 (en) 1993-02-04
BR9103506A (pt) 1992-05-12
EP0473252A3 (en) 1992-08-05
DK0473252T3 (da) 1997-09-15
ID19492A (id) 1998-07-16
MX9100067A (es) 1992-04-01
GR3022971T3 (en) 1997-06-30
GR3031263T3 (en) 1999-12-31
DK0732101T3 (da) 1999-11-22
MY124210A (en) 2006-06-30
US5276057A (en) 1994-01-04
ATE149350T1 (de) 1997-03-15
EP0732101B1 (en) 1999-06-23
CA2039194A1 (en) 1992-03-01
CA2039194C (en) 1997-01-28
DE69124875D1 (de) 1997-04-10
EP0473252A2 (en) 1992-03-04
MY110217A (en) 1998-03-31
AU7395791A (en) 1992-03-05
DE69124875T2 (de) 1997-06-26

Similar Documents

Publication Publication Date Title
HK1011611A1 (en) Use of l-deprenyl for retarding age dependent deterioration of the immune system function in mammals
MX9101046A (es) Anticuerpos novedosos para el tratamiento y prevencion de infeccion de animales y el hombre
IT8522574A0 (it) Composizione farmaceutica eprocedimento per trattare il corpo umano con essa.
GB2240970B (en) Animal feeder with adjustable gate
ES2002083A6 (es) Un metodo para preparar derivados de piroglutamida
DE3851456D1 (de) Synergetische immunostimulierende Zusammensetzung und ihre Verwendung.
EP0335704A3 (en) Treatment of equine livestock
GB2209343B (en) Preparation for prophylaxis and treatment of gastro-intestinal disturbances in farm animals
NZ220242A (en) Regulating fertility in cattle by administering epostane
AU2492892A (en) The device for treatment and prophylaxis of mastitis in animals
EP0154598A3 (en) Method and device for administering medicines or the like to aquatic animals, in particular fish
ZA914219B (en) Transdermal administration to humans and animals
FR2525891B1 (fr) Dispositif de contention humaine equipe d'un referentiel
LV5035A3 (lv) Preparats govju endometritu profilaksei un arstesanai
CS33388A1 (en) Milky fodder mixture for little calves and sucking-pigs rearing
BG52054B2 (en) Device for parasitic disease treatment and prophylaxis
ITMN910022A1 (it) Gruppo termoventilante per l'essicazione del foraggio imballato e sciolto con dispositivo di riciclo dell'aria di essicazione
SU1448442A1 (ru) Препарат для лечения и профилактики вольфартиоза сельскохозяйственных животных
LV5177A3 (lv) Preparats "eridons" govju endometritu profilaksei un arstesanai
CA2113341A1 (en) Use of natamycin for the prevention and control of poultry dactylariosis
IT1171125B (it) Composizione per uso orale particolarmente destinata al trattamento terapeutico di animali

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20060328